Document is current
Any future updates will be listed below
-
Authors
Smith, Corey https://orcid.org/0000-0002-7550-9595
Dasari, Vijayendra https://orcid.org/0000-0003-2106-0945
Srihari, Sriganesh
Le Texier, Laetitia
Solomon, Matthew
Panikkar, Archana
Le, Thuy https://orcid.org/0000-0001-9134-0104
Ambalathingal, George
Raju, Jyothy
Rehan, Sweera
Beagley, Leone
Crooks, Pauline
Khaledi, Panteha https://orcid.org/0009-0004-1983-3851
Mahajan, Arushi
Mukhopadhyay, Pamela
Khanna, Rajiv https://orcid.org/0000-0003-2241-0353
-
Funding
Funding for this research was provided by:
This study was funded by Atara Biotherapeutics
- License Information
-
More Information
Article History
Received: 28 April 2025
Accepted: 12 December 2025
First Online: 7 January 2026
Competing interests
: C.S. and R.K. are listed as inventors on patents and patent applications describing the autologous and allogeneic EBV T-cell therapy. C.S. and R.K. have received research and consultancy funding from Atara Biotherapeutics. The remaining authors declare no competing interests.
